Rein Therapeutics (RNTX)
NASDAQ:RNTX
Total Valuation
Rein Therapeutics has a market cap or net worth of $44.02M. The enterprise value is $40.81M.
Market Cap$44.02M
Enterprise Value$40.81M
Share Statistics
Rein Therapeutics has 28,039,032 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,039,032
Owned by Insiders7.15%
Owned by Institutions31.09%
Financial Efficiency
Rein Therapeutics’s return on equity (ROE) is -2.95 and return on invested capital (ROIC) is -120.27%.
Return on Equity (ROE)-2.95
Return on Assets (ROA)-2.06
Return on Invested Capital (ROIC)-120.27%
Return on Capital Employed (ROCE)-1.22
Revenue Per Employee0.00
Profits Per Employee-4.53M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rein Therapeutics is ―. Rein Therapeutics’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.00
PB Ratio1.74
Price to Fair Value1.74
Price to FCF-1.52
Price to Operating Cash Flow-2.08
PEG Ratio0.01
Income Statement
In the last 12 months, Rein Therapeutics had revenue of 0.00 and earned -49.87M in profits. Earnings per share was -1.96.
Revenue0.00
Gross Profit-1.00K
Operating Income-21.93M
Pretax Income-50.58M
Net Income-49.87M
EBITDA-21.93M
Earnings Per Share (EPS)-1.96
Cash Flow
In the last 12 months, operating cash flow was -19.36M and capital expenditures 0.00, giving a free cash flow of -19.36M billion.
Operating Cash Flow-19.36M
Free Cash Flow-19.36M
Free Cash Flow per Share-0.69
Dividends & Yields
Rein Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change8.28%
50-Day Moving Average1.26
200-Day Moving Average1.30
Relative Strength Index (RSI)69.06
Average Volume (3m)228.95K
Important Dates
Rein Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateApr 6, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Rein Therapeutics as a current ratio of 0.70, with Debt / Equity ratio of 0.00%
Current Ratio0.70
Quick Ratio0.70
Debt to Market Cap0.00
Net Debt to EBITDA0.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Rein Therapeutics has paid -712.00K in taxes.
Income Tax-712.00K
Effective Tax Rate0.01
Enterprise Valuation
Rein Therapeutics EV to EBITDA ratio is -1.20, with an EV/FCF ratio of -1.36.
EV to Sales0.00
EV to EBITDA-1.20
EV to Free Cash Flow-1.36
EV to Operating Cash Flow-1.36
Balance Sheet
Rein Therapeutics has $3.21M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.21M billion.
Cash & Marketable Securities$3.21M
Total Debt$0.00
Net Cash$3.21M
Net Cash Per Share$0.11
Tangible Book Value Per Share-$0.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rein Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside693.65% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast15.35%